Interestingly, leptin administration has been shown to favorably affect the metabolic profile, including dyslipidemia, hepatic steatosis, and insulin resistance, in both lipodystrophic patients (38–42) and mice (19, 43–47), suggesting that the therapeutic potential of AT in rescuing lipodystrophy-associated metabolic derangements may at least partially depend on proper leptin signaling. The gene discussed is LEP; the disease is lipodystrophy.